Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Muggia

Showing results (271-280 of 317) with videos related to

Pageof 32
Sort By:
Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.
The American Journal of Medicine|April 1, 1985
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breastJ L Speyer, M D Green, N Dubin, et al.
Journal of the National Cancer Institute|July 21, 1993
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesisM S Ray, F M Muggia, C G Leichman, et al.
Cancer Treatment Reports|December 1, 1984
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot studyM Levin, K J Pandya, J D Khandekar, et al.
Investigational New Drugs|February 1, 1991
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group studyJ A Kish, K Kopecky, M K Samson, et al.
Cancer Treatment Reports|January 1, 1980
Phase II trials: use of a clinical tumor panel and overview of current resources and studiesF M Muggia, M Rozencweig, D F Chiuten, et al.
Cancer Research|December 1, 1993
Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease responseF A Blommaert, C Michael, P M Terheggen, et al.
Investigational New Drugs|January 1, 1994
Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical toleranceF M Muggia, A Tulpule, A Retzios, et al.
Cancer|February 1, 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancerL B Saltz, C G Leichman, C W Young, et al.
Cancer Research|August 15, 1993
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignanciesE Reed, R J Parker, I Gill, et al.
Pageof 32

Showing results (271-280 of 317) with videos related to

Sort By:
Pageof 32
Annals of Internal Medicine|November 1, 1979
Risk factors for doxorubicin-induced congestive heart failureD D Von Hoff, M W Layard, P Basa, et al.
The American Journal of Medicine|April 1, 1985
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breastJ L Speyer, M D Green, N Dubin, et al.
Journal of the National Cancer Institute|July 21, 1993
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesisM S Ray, F M Muggia, C G Leichman, et al.
Cancer Treatment Reports|December 1, 1984
Phase II study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot studyM Levin, K J Pandya, J D Khandekar, et al.
Investigational New Drugs|February 1, 1991
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group studyJ A Kish, K Kopecky, M K Samson, et al.
Cancer Treatment Reports|January 1, 1980
Phase II trials: use of a clinical tumor panel and overview of current resources and studiesF M Muggia, M Rozencweig, D F Chiuten, et al.
Cancer Research|December 1, 1993
Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease responseF A Blommaert, C Michael, P M Terheggen, et al.
Investigational New Drugs|January 1, 1994
Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical toleranceF M Muggia, A Tulpule, A Retzios, et al.
Cancer|February 1, 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancerL B Saltz, C G Leichman, C W Young, et al.
Cancer Research|August 15, 1993
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignanciesE Reed, R J Parker, I Gill, et al.
Pageof 32